Search
Bromothalonil
go.drugbank.com/drugs/DB14199ApprovedIn 2005, MDBGN was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].
Ipratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigational[A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol
Xanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigational[L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity … [A264514] Xanomeline is a muscarinic agonist that was approved for the treatment of schizophrenia by the FDA in September 2024, becoming the first approved treatment for schizophrenia to target muscarinic
AeroLEF
go.drugbank.com/drugs/DB05000InvestigationalAeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia for patients experiencing acut...
Candoxatril
go.drugbank.com/drugs/DB00616ExperimentalCandoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.
Aztreonam
go.drugbank.com/drugs/DB00355ApprovedInvestigationalA monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinf...
Human interferon omega-1
go.drugbank.com/drugs/DB05472InvestigationalThere are multiple routes for administration of omega interferon: injection, an implantable subcutaneous drug delivery system, and an oral formulation. … It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering.
AAV1-FS344
go.drugbank.com/drugs/DB17855InvestigationalAAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor.
Omega-3-acid ethyl esters
go.drugbank.com/drugs/DB09539ApprovedInvestigationalOmega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849].
Acetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawn[L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964.